Clinical Pharmacy & Pharmacology Research Institute, Affiliated Hospital of Guilin Medical University, Guilin 541001, China.
Laboratory of Hepatobiliary and Pancreatic Surgery, Affiliated Hospital of Guilin Medical University, Guilin 541001, China.
Dis Markers. 2022 Nov 18;2022:9119423. doi: 10.1155/2022/9119423. eCollection 2022.
Triptolide (TP) has demonstrated innumerous biological effects and pharmacological potential against different cancer types. Hepatocellular carcinoma has a high incidence in men, and its incidence is increasing year by year. Studies have shown that angiogenesis plays an important role in the formation of tumors and that angiogenesis is closely related to tumor growth and metastasis. Deregulation of sphingolipids signaling has been associated with several pathological conditions, including cancer. In the present study, we aimed at exploring the potential molecular mechanism of TP's antivascular and antitumor effects in vitro from the perspective of sphinolipids. Human umbilical vein endothelial cells (HUVECs) and HepG2 cells were, respectively, treated with different concentrations of TP and transfected. Then, the effect of HUVECs on HepG2 cells was investigated using a three-dimensional coculture model system. CCK-8 assay was performed for cell proliferation. Cell migration and invasion abilities were assessed using the transwell assay. Cell adhesion and tube formation were detected by Matrigel. RT-PCR and western blotting were used to detect the mRNA and protein expression. The S1P production was measured via ELISA assay. Our results showed that TP inhibited HUVECs and HepG2 cells proliferation, migration, invasion, adhesion, angiogenesis, and serine palmitoyltransferase long chain base subunit 2 (SPTLC2) expression; upregulating SPTLC2 facilitated the proliferation, migration, invasion, adhesion, angiogenesis, and sphingosine-1-phosphate (S1P) production of HUVECs and HepG2 cells, while interfering with SPTLC2 expression inhibited them; HUVECs facilitated the proliferation, migration, invasion, S1P production, S1PR1, and S1PR2 expression of HepG2 cells, while S1PR3 expression was decreased. In conclusion, SPTLC2 may be associated with the antivascular and antitumor effects of TP, and SPTLC2 is expected to become a new marker for tumor therapy. HUVECs can promote the proliferation, migration, and invasion of HepG2 cells, which may be related to the S1P/sphingosine-1-phosphate receptor (S1PR) signaling pathway.
雷公藤红素(TP)具有许多针对不同癌症类型的生物学效应和药理学潜力。肝细胞癌在男性中发病率较高,且呈逐年上升趋势。研究表明,血管生成在肿瘤的形成中起着重要作用,血管生成与肿瘤的生长和转移密切相关。鞘脂信号的失调与包括癌症在内的几种病理状况有关。在本研究中,我们旨在从鞘脂的角度探讨 TP 体外抗血管生成和抗肿瘤作用的潜在分子机制。分别用不同浓度的 TP 和转染处理人脐静脉内皮细胞(HUVECs)和 HepG2 细胞,然后用三维共培养模型系统研究 HUVECs 对 HepG2 细胞的影响。用 CCK-8 法检测细胞增殖。用 Transwell 法检测细胞迁移和侵袭能力。用 Matrigel 检测细胞黏附和管形成。用 RT-PCR 和 Western blot 检测 mRNA 和蛋白表达。用 ELISA 法测定 S1P 产量。结果表明,TP 抑制 HUVECs 和 HepG2 细胞增殖、迁移、侵袭、黏附、血管生成和丝氨酸棕榈酰转移酶长链碱基亚基 2(SPTLC2)表达;上调 SPTLC2 促进 HUVECs 和 HepG2 细胞增殖、迁移、侵袭、黏附、血管生成和鞘氨醇-1-磷酸(S1P)产生,而干扰 SPTLC2 表达则抑制它们;HUVECs 促进 HepG2 细胞增殖、迁移、侵袭、S1P 产生、S1PR1 和 S1PR2 表达,而 S1PR3 表达降低。总之,SPTLC2 可能与 TP 的抗血管生成和抗肿瘤作用有关,SPTLC2 有望成为肿瘤治疗的新标志物。HUVECs 可促进 HepG2 细胞的增殖、迁移和侵袭,这可能与 S1P/鞘氨醇-1-磷酸受体(S1PR)信号通路有关。